CAS: 106362-34-9; (S)-2-((2S,5S,8S,11S,14R)-14-Amino-2,5,8-Tris((R)-1-Hydroxyethyl)-11-(Hydroxymethyl)-4,7,10,13-Tetraoxo-3,6,9,12-Tetraazapentadecanamido)-N1-((S)-1-(((2S,3R)-1-Amino-3-Hydroxy-1-Oxobutan-2-yl)Amino)-3-(4-Hydroxyphenyl)-1-Oxopropan-2-yl)Succinamide
该化合物是一种合成乙酸,由氨酸序列组成,包括D-alaine,Seine,Teleonine,paragine和Tyrosine.该化合物的特点是其薄膜功能组,有助于其生物系统的稳定与溶解.乙酸成分表明存在一种乙酸组,能够影响该化合物与生物膜及其总体药用植物皮皮皮的相互作用.像这一组一样,它往往展示出特定的生物活动,有可能作为分子信号或影响代谢途径.D-amino酸(D-alain)的立体化学学还可能影响其生物活动及抗酶降解.
- 英文名称(S)-2-((2S,5S,8S,11S,14R)-14-Amino-2,5,8-Tris((R)-1-Hydroxyethyl)-11-(Hydroxymethyl)-4,7,10,13-Tetraoxo-3,6,9,12-Tetraazapentadecanamido)-N1-((S)-1-(((2S,3R)-1-Amino-3-Hydroxy-1-Oxobutan-2-yl)Amino)-3-(4-Hydroxyphenyl)-1-Oxopropan-2-yl)Succinamide
- 中文名称D-丙氨酰-丝氨酰-苏氨酰-苏氨酰-苏氨酰-天冬氨酰胺酰-酪氨酰-苏氨酰胺
- IUPAC名称(S)-2-((2S,5S,8S,11S,14R)-14-amino-2,5,8-tris((R)-1-hydroxyethyl)-11-(hydroxymethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazapentadecanamido)-N1-((S)-1-(((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)succinamide
- 其它别名Dapta(Tfa); D-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-Nh2; 3-Quinolinecarboxylic Acid, 7-(3-Amino-1-Pyrrolidinyl)-8-Chloro-1-Cyclopropyl-6-Fluoro-1,4-Dihydro-4-Oxo-, Hydrochloride (1:1)
- CAS编号106362-34-9
- MFCD编号:MFCD00076838
- FDA UNII编号:J208V4ZMP2
- 分子式:C35H56N10O15
- 分子量:856.89
- 产品CID: 103888
- 产品分类Inhibitors/Agonists → Anti-infection → HIV Protease | Inhibitors/Agonists → Anti-infection → HIV | Inhibitors/Agonists → Immunology/Inflammation → CCR
物理性质
合成工艺路线路线简述
专利信息
专利号:US-2022401561-A1
优先权日:2019-09-30
标题 :Protein-macromolecule conjugates and methods of use thereof
发明人：SONG YUNTAO; LI HUI; ZHOU HAIPING; LIAO CHUAN
权利人:BEIJING XUANYI PHARMASCIENCES CO LTD
摘要:The present disclosure provides protein-macromolecule conjugates, releasable linkers, and macromolecules, as defined herein. The disclosed conjugates provide unique properties that ae based at least upon the properties of linker and number of linker-Macromolecule moieties. Also provided herein are a method of synthesis and use of conjugates in treating diseases and disorders.
网址: https://www.cellmano.com
电话: 0551-65326643 18156095617👤
销售电话:0551-65326643 18156095617
邮箱：info@cellmano.com
电话: 0551-65326643 18156095617👤
📞合肥赛曼诺生物科技有限公司 ⚠️参考联系方式
销售电话:0551-65326643 18156095617
邮箱：info@cellmano.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领，请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实，百琢研不参与任何交易。企业认领注册入口→
⚠️ 未注册 · 未认证企业
备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议， 请通过页面底部联系方式告知我们，我们会尽快处理。第 1 / 1 页
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Ahmad SF, Ansari MA, Nadeem A, Bakheet SA, Alotaibi MR, Alasmari AF, Alshammari MA, Al-Mazroua HA, Attia SM. DAPTA, a C-C chemokine receptor 5 (CCR5) antagonist attenuates immune aberrations by downregulating Th9/Th17 immune responses in BTBR T+ Itpr3tf/J mice. Eur J Pharmacol. 2019 Mar 5;846:100-108. doi: 10.1016/j.ejphar.2019.01.016. Epub 2019 Jan 15. 1(1):51-67. doi: 10.2174/1570162033352066. 47(21):7290-7299. doi: 10.1039/c8dt01232f. 26(4):1169-1178. doi: 10.1007/s12350-018-1203-1. Epub 2018 Feb 7. 67(2):83-92. doi: 10.1016/j.antiviral.2005.03.007. 18(5):285-95. doi: 10.1177/095632020701800504. 52(11):6635-47. doi: 10.1021/ic4006746. Epub 2013 May 21.
379:104580. doi: 10.1016/j.cellimm.2022.104580. Epub 2022 Jul 20. 24(7):1093-8. doi: 10.1016/s0196-9781(03)00176-1. 13(19):2868-2880. doi: 10.1002/asia.201800799. Epub 2018 Aug 31. 26(4):1179-1181. doi: 10.1007/s12350-018-1248-1. Epub 2018 Mar 7.
12: Nowak-Sliwinska P, van Beijnum JR, Casini A, Nazarov AA, Wagnieres G, van den Bergh H, Dyson PJ, Griffioen AW. Organometallic ruthenium(II) arene compounds with antiangiogenic activity. J Med Chem. 2011 Jun 9;54(11):3895-902. doi: 10.1021/jm2002074. Epub 2011 May 16. 47(13):5641-8. doi: 10.1021/ic7021903. Epub 2008 Apr 30. 18(3):1386-1396. doi: 10.1021/acs.molpharmaceut.0c01183. Epub 2021 Feb 16.
合成参考文献
参考文献:10.1016/s0166-3542(01)00163-2
摘要:Ruff MR, Melendez-Guerrero LM, Yang QE, Ho WZ, Mikovits JW, Pert CB, Ruscetti FA. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res. 2001 Oct;52(1):63–75. doi: 10.1016/s0166-3542(01)00163-2.
📝 需求与反馈
尽可能描述清楚需求与问题信息
